我們已在上線! 進一步了解
STXS圖示

Stereotaxis

1.01 USD
-0.04
3.81%
收盤時 已更新 10月16日 下午4:00 EDT
1天
-3.81%
5天
-9.01%
1個月
-23.48%
3個月
-38.79%
6個月
-49.75%
今年迄今
-56.47%
1年
-66.67%
5年
-82.37%
10年
-69.76%
 

關於: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

員工: 131

新聞

正面
中性
負面
市場情緒 3個月
正面 12.5%
中性 75%
負面 12.5%
中性
GlobeNewsWire
上個月
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026
New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026
中性
GlobeNewsWire
上個月
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged in Hungary has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system, just over a month after launching its robotic cardiology program.
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
中性
Seeking Alpha
2 個月前
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
正面
MarketBeat
2 個月前
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
Stereotaxis Q2 Earnings Call Highlights
負面
Zacks Investment Research
2 個月前
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
中性
GlobeNewsWire
2 個月前
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
中性
GlobeNewsWire
2 個月前
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
中性
GlobeNewsWire
2 個月前
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary.
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
中性
GlobeNewsWire
3 個月前
Stereotaxis Completes Acquisition of Robocath
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.
Stereotaxis Completes Acquisition of Robocath
正面
MarketBeat
5 個月前
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.
Stereotaxis Q1 Earnings Call Highlights
價格圖表採用Lightweight Charts™實作